Filing Flows › Dare Bioscience (DARE) › Q3 2025
Dare Bioscience (DARE) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Dare Bioscience (DARE) reported revenue of $2K for the third quarter 2025 (Q3 2025), -95% from a year earlier.
Dare Bioscience, Q3 2025: revenue $2K (-95% year over year), net loss $3.6M, operating cash flow −$442K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2K | — | -95% |
| Operating profit | −$3.7M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$442K | — | — |
What changed
Revenue was $2K in Q3 2025, down 95% year over year.
Operating costs exceeded revenue by $3.7M, an operating margin of -162340.8%. Total costs fell 22% while revenue fell 95%. The fastest-growing cost line was General & admin (+22%). The quarter ended with a net loss of $3.6M.
Operating cash flow was −$442K. Non-cash charges added back $470K of depreciation and amortization and $403K of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of $175K exceeded it, leaving free cash flow of −$617K.
Questions
What was Dare Bioscience's revenue in the third quarter 2025?
Dare Bioscience (DARE) reported revenue of $2K for the third quarter 2025 (Q3 2025), -95% from a year earlier.
Source: Dare Bioscience 10-Q on SEC EDGAR.